BiotechTube

Pathogen-Reduced Plasma + Crystalloid Solutions

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns

Trial Timeline

Aug 17, 2022 → Sep 29, 2024

NCT ID
NCT04681638

About Pathogen-Reduced Plasma + Crystalloid Solutions

Pathogen-Reduced Plasma + Crystalloid Solutions is a approved stage product being developed by Cerus for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT04681638. Target conditions include Burns.

What happened to similar drugs?

2 of 5 similar drugs in Burns were approved

Approved (2) Terminated (2) Active (3)
✅Ceftolozane/tazobactamMerckApproved
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04681638ApprovedTerminated

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
Ceftolozane/tazobactamMerckApproved
35
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30